Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00382291 |
This study will develop and evaluate a new behavioral test to measure certain side effects linked to antidepressant use and will evaluate the effectiveness of the medication sertraline plus cognitive behavioral therapy to treat people with obsessive-compulsive disorder.
Condition | Intervention |
---|---|
Obsessive-Compulsive Disorder |
Drug: Sertraline Drug: Placebo Behavioral: Cognitive behavioral therapy (CBT) |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Parallel Assignment |
Official Title: | SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder |
Estimated Enrollment: | 140 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | August 2011 |
Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Sertraline and cognitive behavioral therapy
|
Drug: Sertraline
Sertraline will be administered in standard dosing or slow titration. Treatment with sertraline will last 18 weeks.
Behavioral: Cognitive behavioral therapy (CBT)
CBT treatment will begin at Week 4 of antidepressant treatment. CBT will include education, training, and identifying repetitive behaviors of participants. Participants will learn how to respond to repetitive behaviors in a positive manner.
|
2: Active Comparator
Placebo and cognitive behavioral therapy
|
Drug: Placebo
The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
Behavioral: Cognitive behavioral therapy (CBT)
CBT treatment will begin at Week 4 of antidepressant treatment. CBT will include education, training, and identifying repetitive behaviors of participants. Participants will learn how to respond to repetitive behaviors in a positive manner.
|
Obsessive-compulsive disorder (OCD) is an anxiety disorder that is associated with recurring repetitive behaviors and persistent unwanted thoughts.
People with OCD often carry out ritual-like behaviors such as counting, cleaning, or washing their hands in order to momentarily ease their anxiety. A current treatment for people with OCD is the class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). A recent re-analysis of clinical trials on children with psychiatric conditions found that the risk of suicidal thoughts and behavior when on SSRI-antidepressants was considerably higher than when on placebo. The data also revealed that antidepressant-associated suicidal behavior was not limited to children with depression, but also affected children with OCD and other anxiety disorders. Although the process responsible for increased suicidality is unknown, it may be initiated by a set of symptoms collectively called SSRI induced activation syndrome, which is thought to be common, particularly in children and teens. However, there is a lack of knowledge on this syndrome, including its role in suicidal behavior and how it can be prevented. This study will develop and evaluate a new behavioral test to measure certain side effects linked to antidepressant use. This study will also evaluate the effectiveness of the SSRI sertraline plus cognitive behavioral therapy (CBT) to treat people with OCD.
This double-blind study will be divided into two phases. Phase 1 will involve the development and evaluation of a new behavioral test to measure antidepressant side effects. Participants will attend a 2-hour screening interview during which they will be asked to describe any side effects experienced from antidepressant medications and to rate how problematic these side effects are for them. Participants will be contacted by phone 1 week later to answer questions repeated from the interview. Participation in Phase 1 will last about 10 days.
Phase 2 will comprise the medication treatment portion of the study. Potential participants will undergo an initial screening visit that will include an interview on psychological symptoms associated with OCD and possible family history of OCD. Eligible participants will then undergo a physical exam, blood draw, DNA sampling, and pregnancy test if applicable. Participants will be randomly assigned to receive either sertraline or placebo daily for 18 weeks. At weekly study visits, participants will receive their study drug, complete questionnaires about symptoms of OCD, and undergo vital sign measurements. At specified visits, participants will also perform a task (Stop Signal Task) on a computerized assessment device to measure attention and impulse control and may have blood drawn. For the first 4 weeks of Phase 2, participants will wear a wristwatch-like device (actigraph) to monitor sleep patterns. During the first three visits, participants will receive supportive psychotherapy. At Visit 4, participants will begin receiving 60-minute CBT sessions, which will continue until the final visit. The final visit will include a second physical exam, questionnaires, and blood testing.
Ages Eligible for Study: | 7 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Dana Mason, BS | 352-273-8540 | dmason@ufl.edu |
United States, Florida | |
University of Florida | Recruiting |
Gainesville, Florida, United States, 32611 | |
University of South Florida | Recruiting |
Tampa, Florida, United States, 33701 | |
Principal Investigator: Tanya Murphy, MD, MS |
Principal Investigator: | Tanya K. Murphy, MD | University of Florida |
Responsible Party: | University of Florida ( Regina Bussing, MD ) |
Study ID Numbers: | R01 MH078594, DSIR 84-CTM |
Study First Received: | September 28, 2006 |
Last Updated: | March 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00382291 History of Changes |
Health Authority: | United States: Federal Government |
OCD Antidepressive Agents, Second-Generation Placebos Cognitive Behavior Therapy |
Child Psychiatry Activation Syndrome Psychometrics |
Neurotransmitter Agents Anxiety Disorders Mental Disorders Psychotropic Drugs Sertraline |
Antidepressive Agents, Second-Generation Serotonin Uptake Inhibitors Serotonin Antidepressive Agents Obsessive-Compulsive Disorder |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents |
Pathologic Processes Anxiety Disorders Mental Disorders Therapeutic Uses Sertraline Antidepressive Agents, Second-Generation Central Nervous System Agents Obsessive-Compulsive Disorder Antidepressive Agents |